Revenio Group Oyj (CHIX:REG1VH) ROE %: 8.62% (As of Mar. 2026) — 63% Below Median


CHIX:REG1VH Revenio Group Oyj CHIX:REG1VH
76 GF Score
Price €16.47
GF Value €40.41
! 2 Warning Signs
View Full Analysis

What is Revenio Group Oyj ROE %?

Revenio Group Oyj CHIX:REG1VH 76 ROE % is 8.62% as of Mar. 2026, which is 63% below its 10-year median of 23.03. GuruFocus rates CHIX:REG1VH with a GF Score™ of 76/100 and a GF Value™ of €40.41. The stock has 2 warning signs investors should review. Among 798 Medical Devices & Instruments companies, Revenio Group Oyj ranks better than 83.83% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Revenio Group Oyj's annualized net income for the quarter that ended in Mar. 2026 was €10.0 Mil. Revenio Group Oyj's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was €116.0 Mil. Therefore, Revenio Group Oyj's annualized ROE % for the quarter that ended in Mar. 2026 was 8.62%.

The historical rank and industry rank for Revenio Group Oyj's ROE % or its related term are showing as below:

CHIX:REG1Vh' s ROE % Range Over the Past 10 Years
Min: 14.08   Med: 23.03   Max: 47.58
Current: 14.08

During the past 13 years, Revenio Group Oyj's highest ROE % was 47.58%. The lowest was 14.08%. And the median was 23.03%.

CHIX:REG1Vh's ROE % is ranked better than
83.83% of 798 companies
in the Medical Devices & Instruments industry
Industry Median: 2.41 vs CHIX:REG1Vh: 14.08

Revenio Group Oyj  (CHIX:REG1Vh) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=10/116.001
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(10 / 109.2)*(109.2 / 149.423)*(149.423 / 116.001)
=Net Margin %*Asset Turnover*Equity Multiplier
=9.16 %*0.7308*1.2881
=ROA %*Equity Multiplier
=6.69 %*1.2881
=8.62 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=10/116.001
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (10 / 13.2) * (13.2 / 9.2) * (9.2 / 109.2) * (109.2 / 149.423) * (149.423 / 116.001)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7576 * 1.4348 * 8.42 % * 0.7308 * 1.2881
=8.62 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Revenio Group Oyj ROE % Related Terms


Revenio Group Oyj ROE % Historical Data

* Premium members only.

The historical data trend for Revenio Group Oyj's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revenio Group Oyj ROE % Chart

Revenio Group Oyj Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.38 25.69 20.03 17.82 15.66

Revenio Group Oyj Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.29 11.46 17.24 19.67 8.62

CHIX:REG1VH vs ABT, SYK, MDT: ROE % Comparison

For the Medical Devices subindustry, Revenio Group Oyj's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revenio Group Oyj ROE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's ROE % distribution charts can be found below:

* The bar in red indicates where Revenio Group Oyj's ROE % falls into.


CHIX:REG1VH
76GF Score
Revenio Group Oyj CHIX:REG1VH
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revenio Group Oyj ROE % Calculation

Revenio Group Oyj's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=17.412/( (107.709+114.702)/ 2 )
=17.412/111.2055
=15.66 %

Revenio Group Oyj's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=10/( (114.702+117.3)/ 2 )
=10/116.001
=8.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 8.62% mean?
Revenio Group Oyj (CHIX:REG1VH) has a ROE % of 8.62% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Revenio Group Oyj and its competitors. This is 63% below median its historical median of 23.03. Over the past decade, Revenio Group Oyj's ROE % has ranged from 14.08 to 47.58. According to the industry distribution chart, Revenio Group Oyj ranks #129 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 16.2%.
Is Revenio Group Oyj's ROE % too high?
Revenio Group Oyj's current ROE % of 8.62% is 63% below median its 10-year median of 23.03. Over the past 10 years, this metric has ranged from a low of 14.08 to a high of 47.58. The Medical Devices & Instruments industry median ROE % is 2.41. Revenio Group Oyj's value of 8.62% is 257.7% above this industry median. Based on the distribution chart, Revenio Group Oyj ranks #129 out of 798 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Revenio Group Oyj has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #129 out of 798 companies for ROE %. This places Revenio Group Oyj in the top 16% of its industry — outperforming the majority of peers. The industry median ROE % is 2.41. Revenio Group Oyj's value of 8.62% is 257.7% above this benchmark. Historically, Revenio Group Oyj's own ROE % has ranged from 14.08 to 47.58 over the past decade. While the company's 10-year median is 23.03 vs. the industry median of 2.41, Revenio Group Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.41, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current ROE % of 8.62% is 257.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Revenio Group Oyj and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current ROE % is 8.62%, which is 63% below median its own 10-year median of 23.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Revenio Group Oyj (CHIX:REG1VH) has a current ROE % of 8.62%. The stock's GF Value™ is €40.41, compared to a current price of €16.47 — trading 59.2% below its estimated fair value. The current ROE % is 8.62%, which is 63% below median its 10-year median of 23.03 and 257.7% above the Medical Devices & Instruments industry median of 2.41. Revenio Group Oyj's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Revenio Group Oyj (CHIX:REG1VH), the current ROE % is 8.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Revenio Group Oyj (CHIX:REG1VH) Overvalued in 2026?

Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued. The current stock price of €16.47 is trading 59.2% below its estimated GF Value™ of €40.41.

Key valuation signals for CHIX:REG1VH:

  • ROE %: 8.62% (63% below median its 10-year median of 23.03)
  • GF Value™: €40.41 vs. price of €16.47 (59.2% below fair value)
  • GF Score™: 76/100 with 2 warning signs
  • Industry Position: 257.7% above the Medical Devices & Instruments median (#129 of 798)

No single metric tells the full story. See the CHIX:REG1VH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Revenio Group Oyj Business Description

Address Harkahaankuja 7, Vantaa, FIN, 01730
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
76GF Score

Get the complete analysis for CHIX:REG1VH

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.47
Price
€40.41
GF Value